K-V Pharmaceutical Co. Cl A – Registration Rights Agreement (September 23rd, 2013)
THIS REGISTRATION RIGHTS AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this "Agreement") is entered into as of September 16, 2013, by and among K-V Pharmaceutical Company, a Delaware corporation (the "Company"), and the persons identified on Schedule A hereto (each, a "Holder").
K-V Pharmaceutical Co. Cl A – STOCKHOLDERS' AGREEMENT OF K-V Pharmaceutical Company (September 23rd, 2013)
THIS STOCKHOLDERS' AGREEMENT, dated as of September 16, 2013 (this "Agreement"), by and among K-V Pharmaceutical Company, a Delaware corporation (the "Company"), each Investor, each Person who beneficially owns any shares of Common Stock as of the date hereof, each Person receiving any shares of Common Stock on the date hereof and each other Person who from time to time beneficially owns any shares of Common Stock and is deemed a party to this Agreement in accordance with the provisions herein and in the Certificate of Incorporation (collectively, the Investors and each such other Person, the "Holders," and, individually, a "Holder").
K-V Pharmaceutical Co. Cl A – Share Purchase Agreement (September 5th, 2013)
This Share Purchase Agreement (this "Agreement") is dated as of the June 21, 2013, and is entered into by and among: (i) Capital Ventures International ("CVI"), (ii) (A) Greywolf Capital Overseas Master Fund, (B) Greywolf Capital Partners II LP, and (C) Greywolf Opportunities Fund LLC ("collectively, "Greywolf"), (iii) (A) Kingdon Associates, (B) Kingdon Credit Master Fund L.P., (C) Kingdon Family Partnership, L.P., and (D) M. Kingdon Offshore Master Fund L.P. (collectively, "Kingdon"), and (iv) Deutsche Bank Securities Inc. ("Deutsche Bank" together with CVI, Greywolf, and Kingdon, the "Investors"); Silver Point Finance, LLC, acting individually or through one or more of its affiliates or funds (the "Assignee"); and K-V Pharmaceutical Company (the "Company"). The Investors, the Assignee and the Company are collectively referred to herein as the "Parties" and individually as a "Party." Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the
K-V Pharmaceutical Co. Cl A – Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. And Its Affiliated Debtors (July 12th, 2013)
Nothing contained herein shall constitute an offer, acceptance or a legally binding obligation of the Debtors or any other party in interest and this Plan is subject to approval of the Bankruptcy Court and other customary conditions. This Plan is not an offer with respect to any securities. This is not a solicitation of acceptances or rejections of the Plan. Acceptances or rejections with respect to this Plan may not be solicited until a disclosure statement has been approved by the United States Bankruptcy Court for the Southern District of New York. Such a solicitation will only be made in compliance with applicable provisions of securities and/or bankruptcy laws. YOU SHOULD NOT RELY ON THE INFORMATION CONTAINED IN, OR THE TERMS OF, THIS PLAN FOR ANY PURPOSE (INCLUDING IN CONNECTION WITH THE PURCHASE OR SALE OF THE DEBTORS' SECURITIES) PRIOR TO THE APPROVAL OF THIS PLAN BY THE BANKRUPTCY COURT.
K-V Pharmaceutical Co. Cl A – [Company Letter Head] May 4, 2011 Patrick Christmas One Corporate Woods Drive Bridgeton, MO 63044 Dear Patrick: (December 12th, 2011)
Congratulations! We are excited to have you join KV Pharmaceutical Company, and look forward to your arrival on or before 06/1/2011. This letter provides you with details of your position and benefits, as well as instructions for beginning your new position at KV.